

Risk Reduction Strategies for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Risk Screenings

Prescreening Tools (adolescents and adults)

AUDIT-C Questionnaire, NIDA Quick Screen, TAPS-1 Screening Tool, NIAAA Screening
Tool

Full Assessment Tools (adolescents and adults)

 CAGE Questionnaire, ASSIST Questionnaire[®] MAST Screening Tool, DAST[®] Screening Tool, TAPS-2 Assessment, CRAFFT[®] Screening Tool, BSTAD Screening Tool, S2BI[®] Screening Tool

Drug Testing

- Urine drug screening/testing
- Blood
- Saliva

Prescription Drug Monitoring Program (PDMP)

- All practitioners who prescribe controlled substances must register with the West Virginia Controlled Substance Monitoring Program (CSMP)
- All dispensed controlled medications must be reported to the West Virginia Board of Pharmacy CSMP each 24-hour period and documented to the patient's medical record
- Per West Virginia Code 60A-9-5a, section b: the CSMP must be checked upon initiation of controlled substance, and yearly
- Recommended: Utilize CSMP data with each new prescription and every 3 months for high-risk patients

Patient and Provider Agreements

- Risk versus benefit counseling
- Drug interaction review
- Monitoring of refill requests
- Medication storage and disposal techniques
- Drug diversion consequences
- Pill counts as needed

^{*} Please refer to A West Virginia Guide to Evidence-Informed Evaluation, Diagnosis, and Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and comorbid Concerns (The WV ACC Guidelines), available at www.WVADHD.org for a full list of disclaimers (page 4) and references for the content contained in this handout.